Market Exclusive

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has coverage initiated with a Outperform rating and $60.00 price target

Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Today, Royal Bank of Canada initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a Outperform with a price target of $60.00.

There are 11 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is Buy with a consensus target price of $49.4286 per share, a potential 37.34% upside.

Some recent analyst ratings include

Recent Trading Activity for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals Inc. closed the previous trading session at 35.99 −0.79 2.15% with 36.69 shares trading hands.

Exit mobile version